TY - JOUR AU - Shuch, B. AU - Amin, A. AU - Armstrong, A. J. AU - Eble, J. N. AU - Ficarra, V. AU - Lopez-Beltran, A. PY - 2015 DA - 2015// TI - Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity JO - Eur Urol VL - 67 UR - https://doi.org/10.1016/j.eururo.2014.04.029 DO - 10.1016/j.eururo.2014.04.029 ID - Shuch2015 ER - TY - JOUR AU - Leibovich, B. C. AU - Han, K. R. AU - Bui, M. H. AU - Pantuck, A. J. AU - Dorey, F. J. AU - Figlin, R. A. PY - 2003 DA - 2003// TI - Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials JO - Cancer VL - 98 UR - https://doi.org/10.1002/cncr.11851 DO - 10.1002/cncr.11851 ID - Leibovich2003 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus Everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Anandappa, G. AU - Hollingdale, A. AU - Eisen, T. PY - 2010 DA - 2010// TI - Everolimus - a new approach in the treatment of renal cell carcinoma JO - Cancer Manag Res VL - 2 ID - Anandappa2010 ER - TY - JOUR AU - Wullschleger, S. AU - Loewith, R. AU - Hall, M. N. PY - 2006 DA - 2006// TI - TOR signaling in growth and metabolism JO - Cell VL - 124 UR - https://doi.org/10.1016/j.cell.2006.01.016 DO - 10.1016/j.cell.2006.01.016 ID - Wullschleger2006 ER - TY - JOUR AU - Weis, S. M. AU - Cheresh, D. A. PY - 2011 DA - 2011// TI - Tumor angiogenesis: molecular pathways and therapeutic targets JO - Nat Med VL - 17 UR - https://doi.org/10.1038/nm.2537 DO - 10.1038/nm.2537 ID - Weis2011 ER - TY - JOUR AU - Potente, M. AU - Gerhardt, H. AU - Carmeliet, P. PY - 2011 DA - 2011// TI - Basic and therapeutic aspects of angiogenesis JO - Cell VL - 146 UR - https://doi.org/10.1016/j.cell.2011.08.039 DO - 10.1016/j.cell.2011.08.039 ID - Potente2011 ER - TY - JOUR AU - Gupta, S. AU - Spiess, P. E. PY - 2013 DA - 2013// TI - The prospects of pazopanib in advanced renal cell carcinoma JO - Ther Adv Urol VL - 5 UR - https://doi.org/10.1177/1756287213495099 DO - 10.1177/1756287213495099 ID - Gupta2013 ER - TY - JOUR AU - Guertin, D. A. AU - Sabatini, D. M. PY - 2009 DA - 2009// TI - The pharmacology of mTOR inhibition JO - Sci Signal VL - 2 UR - https://doi.org/10.1126/scisignal.267pe24 DO - 10.1126/scisignal.267pe24 ID - Guertin2009 ER - TY - JOUR AU - Battelli, C. AU - Cho, D. C. PY - 2011 DA - 2011// TI - mTOR inhibitors in renal cell carcinoma JO - Therapy VL - 8 UR - https://doi.org/10.2217/thy.11.32 DO - 10.2217/thy.11.32 ID - Battelli2011 ER - TY - JOUR AU - Heng, D. Y. AU - Xie, W. AU - Regan, M. M. AU - Warren, M. A. AU - Golshayan, A. R. AU - Sahi, C. PY - 2009 DA - 2009// TI - Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.4809 DO - 10.1200/JCO.2008.21.4809 ID - Heng2009 ER - TY - JOUR AU - Gerlinger, M. AU - Catto, J. W. AU - Orntoft, T. F. AU - Real, F. X. AU - Zwarthoff, E. C. AU - Swanton, C. PY - 2015 DA - 2015// TI - Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications JO - Eur Urol VL - 67 UR - https://doi.org/10.1016/j.eururo.2014.04.014 DO - 10.1016/j.eururo.2014.04.014 ID - Gerlinger2015 ER - TY - JOUR AU - Albiges, L. AU - Kube, U. AU - Eymard, J. C. AU - Schmidinger, M. AU - Bamias, A. AU - Kelkouli, N. PY - 2015 DA - 2015// TI - Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.07.030 DO - 10.1016/j.ejca.2015.07.030 ID - Albiges2015 ER - TY - JOUR AU - Clevers, H. PY - 2016 DA - 2016// TI - Modeling development and disease with organoids JO - Cell VL - 165 UR - https://doi.org/10.1016/j.cell.2016.05.082 DO - 10.1016/j.cell.2016.05.082 ID - Clevers2016 ER - TY - JOUR AU - Clevers, H. PY - 2011 DA - 2011// TI - The cancer stem cell: premises, promises and challenges JO - Nat Med VL - 17 UR - https://doi.org/10.1038/nm.2304 DO - 10.1038/nm.2304 ID - Clevers2011 ER - TY - JOUR AU - Sato, T. AU - Clevers, H. PY - 2013 DA - 2013// TI - Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications JO - Science VL - 340 UR - https://doi.org/10.1126/science.1234852 DO - 10.1126/science.1234852 ID - Sato2013 ER - TY - JOUR AU - Sachs, N. AU - Clevers, H. PY - 2014 DA - 2014// TI - Organoid cultures for the analysis of cancer phenotypes JO - Curr Opin Genet Dev VL - 24 UR - https://doi.org/10.1016/j.gde.2013.11.012 DO - 10.1016/j.gde.2013.11.012 ID - Sachs2014 ER - TY - JOUR AU - Gao, D. AU - Vela, I. AU - Sboner, A. AU - Iaquinta, P. J. AU - Karthaus, W. R. AU - Gopalan, A. PY - 2014 DA - 2014// TI - Organoid cultures derived from patients with advanced prostate cancer JO - Cell VL - 159 UR - https://doi.org/10.1016/j.cell.2014.08.016 DO - 10.1016/j.cell.2014.08.016 ID - Gao2014 ER - TY - STD TI - Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor evolution as a therapeutic target. Cancer Discov. 2017;7(8):1–13. Epub 2017/07/22 ID - ref19 ER - TY - JOUR AU - McGranahan, N. AU - Swanton, C. PY - 2017 DA - 2017// TI - Clonal heterogeneity and tumor evolution: past, present, and the future JO - Cell VL - 168 UR - https://doi.org/10.1016/j.cell.2017.01.018 DO - 10.1016/j.cell.2017.01.018 ID - McGranahan2017 ER - TY - JOUR AU - Adelaiye, R. AU - Ciamporcero, E. AU - Miles, K. M. AU - Sotomayor, P. AU - Bard, J. AU - Tsompana, M. PY - 2015 DA - 2015// TI - Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-14-0208 DO - 10.1158/1535-7163.MCT-14-0208 ID - Adelaiye2015 ER - TY - JOUR AU - Bieche, I. AU - Vacher, S. AU - Vallerand, D. AU - Richon, S. AU - Hatem, R. AU - De Plater, L. PY - 2014 DA - 2014// TI - Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-178 DO - 10.1186/1471-2407-14-178 ID - Bieche2014 ER - TY - JOUR AU - Jimenez-Valerio, G. AU - Martinez-Lozano, M. AU - Bassani, N. AU - Vidal, A. AU - Ochoa-de-Olza, M. AU - Suarez, C. PY - 2016 DA - 2016// TI - Resistance to antiangiogenic therapies by metabolic Symbiosis in renal cell carcinoma PDX models and patients JO - Cell Rep VL - 15 UR - https://doi.org/10.1016/j.celrep.2016.04.015 DO - 10.1016/j.celrep.2016.04.015 ID - Jimenez-Valerio2016 ER - TY - JOUR AU - Karam, J. A. AU - Zhang, X. Y. AU - Tamboli, P. AU - Margulis, V. AU - Wang, H. AU - Abel, E. J. PY - 2011 DA - 2011// TI - Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma JO - Eur Urol VL - 59 UR - https://doi.org/10.1016/j.eururo.2010.11.043 DO - 10.1016/j.eururo.2010.11.043 ID - Karam2011 ER - TY - JOUR AU - Schuller, A. G. AU - Barry, E. R. AU - Jones, R. D. AU - Henry, R. E. AU - Frigault, M. M. AU - Beran, G. PY - 2015 DA - 2015// TI - The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2685 DO - 10.1158/1078-0432.CCR-14-2685 ID - Schuller2015 ER - TY - JOUR AU - Sivanand, S. AU - Pena-Llopis, S. AU - Zhao, H. AU - Kucejova, B. AU - Spence, P. AU - Pavia-Jimenez, A. PY - 2012 DA - 2012// TI - A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma JO - Sci Transl Med VL - 4 UR - https://doi.org/10.1126/scitranslmed.3003643 DO - 10.1126/scitranslmed.3003643 ID - Sivanand2012 ER - TY - JOUR AU - Tentler, J. J. AU - Tan, A. C. AU - Weekes, C. D. AU - Jimeno, A. AU - Leong, S. AU - Pitts, T. M. PY - 2012 DA - 2012// TI - Patient-derived tumour xenografts as models for oncology drug development JO - Nat Rev Clin Oncol VL - 9 UR - https://doi.org/10.1038/nrclinonc.2012.61 DO - 10.1038/nrclinonc.2012.61 ID - Tentler2012 ER - TY - JOUR AU - Thong, A. E. AU - Zhao, H. AU - Ingels, A. AU - Valta, M. P. AU - Nolley, R. AU - Santos, J. PY - 2014 DA - 2014// TI - Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential JO - Urol Oncol VL - 32 UR - https://doi.org/10.1016/j.urolonc.2013.05.008 DO - 10.1016/j.urolonc.2013.05.008 ID - Thong2014 ER - TY - JOUR AU - VanMeter, A. AU - Signore, M. AU - Pierobon, M. AU - Espina, V. AU - Liotta, L. A. AU - Petricoin, E. F. PY - 2007 DA - 2007// TI - Reverse-phase protein microarrays: application to biomarker discovery and translational medicine JO - Expert Rev Mol Diagn VL - 7 UR - https://doi.org/10.1586/14737159.7.5.625 DO - 10.1586/14737159.7.5.625 ID - VanMeter2007 ER - TY - JOUR AU - Bonci, D. AU - Coppola, V. AU - Patrizii, M. AU - Addario, A. AU - Cannistraci, A. AU - Francescangeli, F. PY - 2016 DA - 2016// TI - A microRNA code for prostate cancer metastasis JO - Oncogene VL - 35 UR - https://doi.org/10.1038/onc.2015.176 DO - 10.1038/onc.2015.176 ID - Bonci2016 ER - TY - JOUR AU - Bonci, D. AU - Coppola, V. AU - Musumeci, M. AU - Addario, A. AU - Giuffrida, R. AU - Memeo, L. PY - 2008 DA - 2008// TI - The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities JO - Nat Med VL - 14 UR - https://doi.org/10.1038/nm.1880 DO - 10.1038/nm.1880 ID - Bonci2008 ER - TY - JOUR AU - Cannistraci, A. AU - Federici, G. AU - Addario, A. AU - Di Pace, A. L. AU - Grassi, L. AU - Muto, G. PY - 2017 DA - 2017// TI - C-met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2016.505 DO - 10.1038/onc.2016.505 ID - Cannistraci2017 ER - TY - JOUR AU - Zabouo, G. AU - Imbert, A. M. AU - Jacquemier, J. AU - Finetti, P. AU - Moreau, T. AU - Esterni, B. PY - 2009 DA - 2009// TI - CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines JO - Breast Cancer Res VL - 11 UR - https://doi.org/10.1186/bcr2215 DO - 10.1186/bcr2215 ID - Zabouo2009 ER - TY - JOUR AU - Nodomi, S. AU - Umeda, K. AU - Saida, S. AU - Kinehara, T. AU - Hamabata, T. AU - Daifu, T. PY - 2016 DA - 2016// TI - CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor JO - Oncogene VL - 35 UR - https://doi.org/10.1038/onc.2016.72 DO - 10.1038/onc.2016.72 ID - Nodomi2016 ER - TY - JOUR AU - Feng, G. AU - Fang, F. AU - Liu, C. AU - Zhang, F. AU - Huang, H. AU - Pu, C. PY - 2012 DA - 2012// TI - CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy JO - Int Urol Nephrol VL - 44 UR - https://doi.org/10.1007/s11255-012-0255-4 DO - 10.1007/s11255-012-0255-4 ID - Feng2012 ER - TY - JOUR AU - Escudier, B. AU - Porta, C. AU - Schmidinger, M. AU - Algaba, F. AU - Patard, J. J. AU - Khoo, V. PY - 2014 DA - 2014// TI - Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu259 DO - 10.1093/annonc/mdu259 ID - Escudier2014 ER - TY - JOUR AU - Schodel, J. AU - Grampp, S. AU - Maher, E. R. AU - Moch, H. AU - Ratcliffe, P. J. AU - Russo, P. PY - 2016 DA - 2016// TI - Hypoxia, hypoxia-inducible transcription factors, and renal Cancer JO - Eur Urol VL - 69 UR - https://doi.org/10.1016/j.eururo.2015.08.007 DO - 10.1016/j.eururo.2015.08.007 ID - Schodel2016 ER - TY - JOUR AU - Masoud, G. N. AU - Li, W. PY - 2015 DA - 2015// TI - HIF-1alpha pathway: role, regulation and intervention for cancer therapy JO - Acta Pharm Sin B VL - 5 UR - https://doi.org/10.1016/j.apsb.2015.05.007 DO - 10.1016/j.apsb.2015.05.007 ID - Masoud2015 ER - TY - JOUR AU - Ravaud, A. AU - Motzer, R. J. AU - Pandha, H. S. AU - George, D. J. AU - Pantuck, A. J. AU - Patel, A. PY - 2016 DA - 2016// TI - Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611406 DO - 10.1056/NEJMoa1611406 ID - Ravaud2016 ER - TY - JOUR AU - Janowitz, T. AU - Welsh, S. J. AU - Zaki, K. AU - Mulders, P. AU - Eisen, T. PY - 2013 DA - 2013// TI - Adjuvant therapy in renal cell carcinoma-past, present, and future JO - Semin Oncol VL - 40 UR - https://doi.org/10.1053/j.seminoncol.2013.05.004 DO - 10.1053/j.seminoncol.2013.05.004 ID - Janowitz2013 ER - TY - JOUR AU - Mentrikoski, M. J. AU - Wendroth, S. M. AU - Wick, M. R. PY - 2014 DA - 2014// TI - Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin JO - Appl Immunohistochem Mol Morphol VL - 22 UR - https://doi.org/10.1097/PAI.0000000000000004 DO - 10.1097/PAI.0000000000000004 ID - Mentrikoski2014 ER - TY - JOUR AU - Barr, M. L. AU - Jilaveanu, L. B. AU - Camp, R. L. AU - Adeniran, A. J. AU - Kluger, H. M. AU - Shuch, B. PY - 2015 DA - 2015// TI - PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma? JO - J Clin Pathol VL - 68 UR - https://doi.org/10.1136/jclinpath-2014-202259 DO - 10.1136/jclinpath-2014-202259 ID - Barr2015 ER - TY - JOUR AU - Gerlinger, M. AU - Rowan, A. J. AU - Horswell, S. AU - Larkin, J. AU - Endesfelder, D. AU - Gronroos, E. PY - 2012 DA - 2012// TI - Intratumor heterogeneity and branched evolution revealed by multiregion sequencing JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1113205 DO - 10.1056/NEJMoa1113205 ID - Gerlinger2012 ER - TY - JOUR AU - Ferlay, J. AU - Steliarova-Foucher, E. AU - Lortet-Tieulent, J. AU - Rosso, S. AU - Coebergh, J. W. AU - Comber, H. PY - 2013 DA - 2013// TI - Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.027 DO - 10.1016/j.ejca.2012.12.027 ID - Ferlay2013 ER - TY - JOUR AU - Ferlay, J. AU - Soerjomataram, I. AU - Dikshit, R. AU - Eser, S. AU - Mathers, C. AU - Rebelo, M. PY - 2015 DA - 2015// TI - Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 JO - Int J Cancer VL - 136 UR - https://doi.org/10.1002/ijc.29210 DO - 10.1002/ijc.29210 ID - Ferlay2015 ER -